Skip to main navigation Skip to search Skip to main content

Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer

  • Suleiman Massarweh
  • , Jessica Moss
  • , Chi Wang
  • , Edward Romond
  • , Stacey Slone
  • , Heidi Weiss
  • , Rouzan G. Karabakhtsian
  • , Dana Napier
  • , Esther P. Black

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Targeting growth factor and survival pathways may delay endocrine-resistance in estrogen receptor-positive breast cancer.

Materials & methods: A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted. Primary end point was response by RECIST after 3 months of sorafenib. Secondary end points included safety, time to progression and biomarker modulation. The study closed early owing to slow accrual.

Results: Eight out of 11 patients had progressive disease on study entry and three had stable disease. Of the ten evaluable patients, seven experienced stable disease (70%) and three experienced progressive diseas (30%), with a median time to progression of 6.1 months (8.4 months in the seven patients on tamoxifen). The serum samples demonstrated a significant reduction in VEGF receptor 2 and PDGF receptor-α. Microarray analysis identified 32 suppressed genes, no induced genes and 29 enriched Kyoto Encyclopedia of Genes and Genomes pathways.

Conclusion: The strategy of adding a targeted agent to endocrine therapy upon resistance may be worthwhile testing in larger studies.

Original languageEnglish (US)
Pages (from-to)2435-2448
Number of pages14
JournalFuture Oncology
Volume10
Issue number15
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • PDGF receptor-α
  • Ras/Raf/MAPK
  • VEGF receptor 2
  • angiogenesis
  • breast cancer
  • endocrine resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer'. Together they form a unique fingerprint.

Cite this